(TRVI) Trevi Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TRVI) Trevi Therapeutics, Inc. Complete Analysis Pack
Trevi Therapeutics: Business Model Canvas at a Glance
Unlock the full strategic blueprint behind Trevi Therapeutics, Inc.'s business model. This concise Business Model Canvas reveals how the company creates value, builds partnerships, and positions itself in a competitive biotech market. Ideal for investors, analysts, and strategists looking for clear, actionable insight—get the full version to dive deeper.
Partnerships
Endo Pharmaceuticals nalbuphine license
Endo Pharmaceuticals gave Trevi Therapeutics rights to develop and market products containing nalbuphine hydrochloride, which is the base active ingredient behind Haduvio. It is Trevi Therapeutics, Inc.'s main named licensing partner, and the program remained in clinical development through 2025 with no approved nalbuphine-based product yet.
Phase IIb/III investigator sites
Trevi Therapeutics, Inc. relies on Phase IIb/III investigator sites to run its 2 late-stage programs in chronic pruritus and IPF cough. These sites enroll patients and collect the efficacy and safety data Trevi needs for pivotal readouts and regulatory filings.
CRO clinical operations vendors
Trevi Therapeutics, Inc. relies on CRO clinical operations vendors to run trial management, site monitoring, and data handling, which keeps headcount lean; clinical-stage biotechs often spend the bulk of R&D on outsourced trial work, not internal staff. In 2025, Trevi reported no product revenue and continued to fund development through outside partners, a common model in biotech.
CMO formulation supply partners
Trevi Therapeutics, Inc. depends on CMO formulation supply partners to make GMP-quality extended-release oral nalbuphine for its ongoing clinical studies, so the drug supply stays trial-ready and compliant. These manufacturers also matter for scale-up, because Trevi needs a reliable path from development batches to larger, commercial-grade supply without breaking quality control.
- GMP supply for active trials
- Supports oral nalbuphine scale-up
- Reduces manufacturing bottlenecks
Dermatology and pulmonology KOLs
Trevi Therapeutics, Inc. relies on dermatology and pulmonology KOLs to shape study design, endpoints, and medical positioning for pruritus and interstitial lung disease. That matters because pruritus affects millions of patients, while ILD and related fibrotic lung disease remain specialist-led markets where KOL input can lift physician trust and trial credibility.
- KOLs refine trial design and endpoints.
- They support adoption in niche specialist markets.
- Their input boosts credibility with physicians.
Trevi’s Key Partnerships Power Two Late-Stage Haduvio Programs
Trevi Therapeutics, Inc. key partnerships center on Endo Pharmaceuticals for nalbuphine rights, plus CROs, CMOs, investigator sites, and KOLs that keep Haduvio trials and supply moving. In 2025, Trevi still had no product revenue and was funding 2 late-stage programs through this outsourced model.
| Partner | Role | 2025/2026 data |
|---|---|---|
| Endo Pharmaceuticals | Nalbuphine license | No approved product |
| CROs/CMOs/sites | Trials and supply | 2 late-stage programs |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Trevi Therapeutics, mapping its biotech strategy, stakeholders, value proposition, and commercial path.
Customizable Excel Spreadsheet
Condenses Trevi Therapeutics’ business model into a quick, editable view for fast pain-point analysis.
Reference Sources
Shows the Trevi Therapeutics, Inc. reference sources behind the analysis, making claims easier to verify and decisions more defensible.
Activities
Phase IIb/III Haduvio trials
Trevi Therapeutics, Inc.'s key activity is running late-stage Phase IIb/III Haduvio trials, its sole clinical asset, to prove benefit in chronic pruritus and persistent cough in idiopathic pulmonary fibrosis. Trial execution is the main value driver, with results that can shape the program's path to registration and future revenue.
Chronic pruritus study execution
Chronic pruritus can affect 40%-80% of people on hemodialysis, and treatment options remain limited, so Trevi Therapeutics, Inc.’s study execution targets a high-burden unmet need. Positive data could support the first major label expansion for Haduvio, if the efficacy and safety package holds up.
IPF cough study execution
Trevi Therapeutics, Inc. is running Haduvio studies in persistent cough tied to idiopathic pulmonary fibrosis, a symptom that affects about 80% of IPF patients and has few approved treatment options. This keeps the program aimed at a high-unmet-need market of roughly 3 million people worldwide and can expand Haduvio’s commercial reach beyond chronic cough.
Regulatory strategy and safety reporting
Trevi Therapeutics, Inc. runs FDA-facing planning and safety reporting for its 1 lead asset, Haduvio, with adverse-event review and submission prep tied to each study. That regulatory work is central to the approval path because it links clinical safety data to the next filing step.
As of its latest 2025 filings, Trevi remained a clinical-stage company with no product sales, so these tasks are a core operating need, not a side function.
- FDA meeting prep
- Adverse-event review
- Submission support
Oral ER formulation development
Trevi Therapeutics, Inc. develops Haduvio, an orally administered extended-release nalbuphine product, so formulation control is central to steady exposure, dose precision, and tolerability. That matters because peak smoothing can reduce side effects while keeping drug levels in range for longer symptom control.
- Oral ER nalbuphine is the core platform.
- Exposure control drives dosing consistency.
- Tolerability depends on release design.
- It underpins Haduvio’s clinical profile.
Trevi’s Engine: Haduvio Trials, FDA Prep, and Safety Reporting
Trevi Therapeutics, Inc. key activities are Haduvio trial execution, FDA prep, and safety reporting. In 2025, it remained clinical-stage with $0 product sales, so these workstreams are its main operating engine.
| Key activity | Latest data |
|---|---|
| Lead asset | 1: Haduvio |
| 2025 sales | $0 |
| Core focus | Phase IIb/III trials |
Delivered as Displayed
Business Model Canvas
This preview shows the actual Trevi Therapeutics, Inc. Business Model Canvas you’ll receive after purchase, not a sample or placeholder. What you see here is a direct snapshot of the final document, with the same structure, content, and formatting included. Once you buy, you’ll get full access to this exact file, ready to use, edit, or present.
Resources
Haduvio asset
Haduvio is Trevi Therapeutics, Inc.'s lead clinical asset and the core of its pipeline, which is concentrated around one program. It is being developed for neurologically mediated conditions, with Trevi still pre-commercial and focused on advancing this single asset through clinical milestones.
Nalbuphine hydrochloride rights
Trevi Therapeutics, Inc.’s key resource is its nalbuphine hydrochloride rights under the Endo agreement, the core intangible asset behind Haduvio. Those rights give Trevi control over development and any future commercialization, and Trevi is still pre-revenue, with no approved products as of its latest FY2025 filing.
Extended-release oral IP
Trevi Therapeutics, Inc.'s extended-release oral nalbuphine IP is the core technical asset, and it sets the product apart from immediate-release nalbuphine by enabling steadier exposure and simpler dosing. That formulation know-how also shapes the development plan, from dose selection to trial design.
Clinical trial data package
In 2025, Trevi Therapeutics, Inc. still had no product revenue, so its clinical trial data package is the core asset. Ongoing Phase IIb/III studies keep building the efficacy and safety evidence needed for future regulatory filings and for partner and investor talks.
- No approved products yet.
- Phase IIb/III data drive filing plans.
- Safety and efficacy are the main proof.
- Supports financing and partnership value.
New Haven headquarters and team
Trevi Therapeutics, Inc. keeps its key resource base in New Haven, Connecticut, where a lean internal team runs R&D, regulatory, and corporate work. That setup fits a clinical-stage model: as of its latest 2025 filings, Trevi had no approved product revenue and stayed focused on pipeline execution and capital discipline.
- New Haven HQ anchors core functions.
- Lean team supports low overhead.
- Best fit for clinical-stage execution.
Trevi’s Core Assets Power Its Pre-Revenue Pipeline
Trevi Therapeutics, Inc.’s key resources are its nalbuphine hydrochloride rights for Haduvio, its extended-release formulation IP, and the Phase IIb/III data package that supports future filings. In FY2025, Trevi Therapeutics, Inc. remained pre-revenue with no approved products, so these assets and its lean New Haven team carried the business.
| Key resource | FY2025 note |
|---|---|
| Haduvio rights | Core intangible asset |
| Clinical data | Phase IIb/III |
| Revenue | No product revenue |
Value Propositions
Potential severe itch treatment
Haduvio targets chronic pruritus, a severe itch disorder with few reliable treatments, so it offers a direct symptom-focused value proposition for patients who still struggle on standard care. In Trevi Therapeutics, Inc.'s latest reports, the program remains the core asset, with the company ending 2025 with about $146 million in cash and marketable securities to fund development.
Potential IPF cough treatment
Trevi Therapeutics, Inc. is studying oral therapy for persistent cough in idiopathic pulmonary fibrosis, where cough affects up to 80% of patients and can sharply reduce quality of life. In a difficult-to-treat market with about 100,000 people living with IPF in the U.S., even modest symptom relief could create clear clinical value.
Orally administered extended-release dosing
Haduvio is Trevi Therapeutics, Inc.'s oral extended-release nalbuphine, designed for twice-daily dosing, which is easier for patients than injections or other complex delivery methods. The extended-release design helps keep drug exposure steadier across the day, which can support more consistent symptom control.
Neurologically mediated symptom focus
Trevi Therapeutics, Inc. frames Haduvio around neurologically mediated symptoms, so the value is fast symptom control, not disease modification. That fits itch and cough biology, with Haduvio in 2 lead programs and 2025 data aimed at chronic pruritus and refractory chronic cough.
- Targets symptom biology
- Matches itch and cough
- 2 lead programs
Single asset, dual indication
Trevi Therapeutics, Inc. is building one oral asset, Haduvio, across 2 cough settings: refractory chronic cough and cough in idiopathic pulmonary fibrosis. That same formulation can serve both, so success in one program can support the other and widen the commercial pool beyond a single niche.
- 1 formulation, 2 indications
- Shared development and launch path
- Broader market than one cough type
Trevi’s Haduvio: Cash-Rich Shot at Severe Itch and Cough
Trevi Therapeutics, Inc.'s value proposition is Haduvio: a twice-daily oral nalbuphine designed to calm severe, neurologically driven itch and cough where current care leaves big gaps. In 2025, Trevi Therapeutics, Inc. ended with about $146 million in cash and marketable securities, giving it runway to push 2 lead programs in chronic pruritus and cough.
| Item | Data |
|---|---|
| Core asset | Haduvio |
| 2025 cash | ~$146M |
| Lead programs | 2 |
Customer Relationships
Specialist physician education
Trevi Therapeutics must educate dermatologists and pulmonologists on Haduvio because these specialists will shape diagnosis and prescribing in chronic cough and pruritus care. With Trevi reporting 2025 cash and equivalents of $107.9 million and no product revenue, specialist education is a core pre-launch investment to build trial-to-prescription uptake.
Medical affairs engagement
Trevi Therapeutics, Inc. needs medical affairs to keep scientific dialogue open with clinicians and investigators across its 2 lead Haduvio programs, chronic cough and pruritus. That evidence-based exchange helps explain the clinical data, build trust before launch, and support credibility in a market with no approved therapy for refractory chronic cough.
Patient support and adherence
Patients with chronic itch or IPF cough need steady support because symptoms are long lasting; cough affects up to 80% of people with IPF, so tracking symptoms and side effects can help keep treatment on track. Support programs that remind, monitor, and coach patients can lift adherence and persistence, which matters most in chronic therapy.
Payer access support
Trevi Therapeutics, Inc. must win payer and pharmacy benefit access before uptake can scale, because specialty drugs often face step edits, prior auth, and formulary gates. In 2025, Trevi reported no product revenue, so reimbursement support and evidence packs for payers are central to future 2026 sales conversion.
- Prior auth can delay starts
- Formulary access drives uptake
- Payer dossiers must prove value
Investigator site support
Trevi Therapeutics, Inc. uses investigator site support to train clinical staff, return data fast, and solve site issues, which helps protect trial quality and keep enrollment moving. This is a core pre-commercial need: Trevi Therapeutics reported no product revenue in 2025, so execution at trial sites is a direct value driver.
- Train sites and reduce protocol errors
- Speed data feedback and query resolution
- Support enrollment and trial retention
- Fit Trevi Therapeutics’ pre-commercial model
Trevi’s Pre-Launch Playbook: Education, Access, and $107.9M Cash
Trevi Therapeutics, Inc. builds Customer Relationships through specialist education, medical affairs, patient support, and payer access work, because Haduvio is still pre-launch and 2025 product revenue was $0. The base is cash and equivalents of $107.9 million at year-end 2025, which funds launch prep and trial-to-prescription conversion.
| 2025 metric | Value |
|---|---|
| Cash and equivalents | $107.9 million |
| Product revenue | $0 |
Channels
Clinical trial sites
Clinical trial sites are Trevi Therapeutics, Inc.'s main channel for Haduvio, because they recruit patients, engage investigators, and generate the clinical data needed in a Phase 2/3 program. In 2025, this site network stayed central to Trevi Therapeutics, Inc.'s clinical-stage model, with no commercial revenue and R&D still the main cash use.
Specialist physician offices
Specialist physician offices are likely the first prescribing point for Trevi Therapeutics, Inc., especially dermatology and pulmonology practices that see the core target patients in concentrated volumes. For launch, that matters: U.S. specialty care now handles a growing share of chronic cough and skin-disease visits, so a focused field force can reach the right prescribers faster.
Medical congresses
Medical congresses let Trevi Therapeutics, Inc. present trial and mechanism data to pulmonologists, sleep specialists, and KOLs who shape treatment use. As a 2025 pre-commercial biotech with $0 product revenue, congress presence is a practical way to build credibility, support partnering talks, and turn Phase 2/3 data into awareness.
Peer-reviewed publications
Trevi Therapeutics, Inc. uses peer-reviewed publications to build clinical credibility and push trial data into specialist channels before any approval, which matters because the Company still has no approved product. For a clinical-stage Company like Trevi Therapeutics, Inc., journal articles can shape neurologist and pulmonologist awareness faster than paid promotion.
- Builds trust before approval
- Spreads data to specialists fast
Specialty pharmacy networks
If approved, Trevi Therapeutics, Inc. would likely use specialty pharmacy networks because Haduvio is a complex, niche therapy that needs controlled dispensing, access support, and patient onboarding. Specialty drugs now account for more than 50% of U.S. drug spend, so this channel fits high-touch products that need prior auth, refill tracking, and adherence support.
- Best fit for complex therapy
- Supports access and onboarding
- Helps manage prior auth
Trevi’s Haduvio Path: From Trials to Specialist Prescribing
Trevi Therapeutics, Inc. relies on clinical trial sites, specialist offices, congresses, publications, and, if approved, specialty pharmacies to move Haduvio from data generation to specialist prescribing. In 2025, the Company had $0 product revenue and R&D remained the main cash use, so these channels were still pre-commercial and evidence-led.
| Channel | Use | 2025 signal |
|---|---|---|
| Trials | Recruit and generate data | No revenue |
| Specialty pharmacy | Access and refill support | Fits complex drugs |
Customer Segments
Chronic pruritus patients
Chronic pruritus patients are a core Haduvio target: they live with severe, persistent itch that can disrupt sleep, work, and daily life. Trevi is building a symptom-directed option for this group, which is large; itch disorders such as prurigo nodularis are estimated to affect about 0.1%–0.2% of adults, and chronic itch can involve millions more.
IPF persistent cough patients
IPF patients with chronic cough are a core Trevi Therapeutics target because cough affects about 70% to 85% of people with idiopathic pulmonary fibrosis and is often hard to control, even with antifibrotic care. This group has high unmet need and a heavy quality-of-life burden, supporting the second core customer segment for Trevi Therapeutics, Inc.
Dermatologists
Dermatologists are a key prescriber group for chronic pruritus, especially in atopic dermatitis, which affects about 16.5 million U.S. adults. They shape diagnosis, treatment choice, and referral paths, so they are a high-value channel for Trevi Therapeutics, Inc. Haduvio development and future uptake.
Pulmonologists
Pulmonologists are a core specialist audience for Trevi Therapeutics, Inc. because they diagnose IPF and manage the chronic cough that affects up to 80% of patients with fibrotic ILD. They are key to Haduvio adoption in respiratory care, especially in a U.S. IPF market often estimated at 100,000+ patients.
- Pulmonologists drive IPF diagnosis
- They treat cough-heavy respiratory disease
- They shape Haduvio uptake
Payers and health systems
Payers and health systems are Trevi Therapeutics, Inc. gatekeepers: they set prior auth, step edits, and coverage, so they shape access and uptake in specialty care. In the U.S., about 160 million people are covered by employer plans, and commercial payers can decide whether a niche therapy scales or stalls.
- Control access rules and reimbursement
- Drive specialty-market uptake
- Act as key economic customers
Trevi’s market hinges on patients, prescribers, and payers
Trevi Therapeutics, Inc. mainly serves two patient groups: people with chronic pruritus, including prurigo nodularis and atopic dermatitis, and people with idiopathic pulmonary fibrosis who have chronic cough. Its key economic buyers are dermatologists, pulmonologists, and payers, because they diagnose, prescribe, and control access for specialty care.
| Segment | Role | Why it matters |
|---|---|---|
| Patients | Chronic itch, IPF cough | High unmet need |
| Clinicians | Dermatologists, pulmonologists | Drive prescribing |
| Payers | Health plans, systems | Control coverage |
Cost Structure
Phase IIb/III trial spend
Trevi Therapeutics, Inc.’s Phase IIb/III trial spend is the biggest cost line, because late-stage studies need patient enrollment, site monitoring, endpoint readouts, and ongoing safety oversight. For a clinical-stage biotech, this can absorb tens of millions of dollars and usually drives most R&D spend.
CRO and site fees
CRO and site fees are a major recurring cash drain for Trevi Therapeutics, Inc. because each added patient, visit, and trial month pushes spend higher. In clinical development, external ops and site costs can make up about 30% to 60% of total trial budgets, so larger or longer studies usually hit this line first.
CMC and manufacturing scale-up
Trevi Therapeutics, Inc. must fund formulation work, GMP batches, stability, and release testing for its extended-release supply, and those CMC costs rise as it moves through 2 Phase 3 programs and into launch prep. In 2025, that usually means more spend on process controls, validation lots, and QA before scale-up can support commercial demand.
Regulatory and quality costs
Trevi Therapeutics, Inc. must fund FDA strategy, compliance, and quality-system work to keep its late-stage program inspection-ready; in 2025, that kind of biopharma overhead sat alongside a cash-and-equivalents balance of about $100 million-plus, so it is a real cost line, not a side task.
- Supports FDA filings
- Keeps inspections ready
- Drives CMC and QA spend
G&A and public company overhead
Trevi Therapeutics, Inc. carries steady G&A and public-company overhead: SEC reporting, audit, legal, finance, board, and New Haven headquarters costs. These expenses recur every quarter and are usually smaller than R&D, but they still shape burn rate and cash needs.
- SEC, audit, legal, finance
- New Haven HQ overhead
- Ongoing, but below R&D
Trevi’s 2025 Spend Still Runs on Trials, CROs, and CMC
Trevi Therapeutics, Inc.’s 2025 cost structure is still trial-heavy: Phase 2b/3 and Phase 3 study spend, CRO and site fees, and CMC work drive most cash burn. G&A stays smaller but recurring, while FDA, QA, and compliance add steady overhead; cash and equivalents were about $100 million-plus in 2025.
| Cost line | Main driver |
|---|---|
| Clinical trials | Patient, site, monitoring spend |
| CRO/site fees | Added visits and trial months |
| CMC/QA | GMP, validation, release testing |
| G&A | SEC, legal, audit, HQ |
Revenue Streams
Future Haduvio prescription sales
Haduvio’s main long-term revenue stream is post-approval prescription sales, first through specialty physicians and then payer-covered channels. Trevi Therapeutics, Inc. still had no product revenue in fiscal 2025, so this remains the core commercial upside, not current revenue.
Endo license royalties
Endo license royalties give Trevi Therapeutics, Inc. a non-dilutive revenue path if nalbuphine products reach market; in FY2025, this was still a contingent source, not a reported sales stream. The royalty terms turn the Endo agreement into a key contractual monetization engine, with income tied to future commercialization rather than current product revenue.
Upfront and milestone payments
Upfront and milestone payments from licensing and development deals can bring in cash before launch, and for Trevi Therapeutics, Inc., which reported $0 product revenue in its latest filings, that non-dilutive income matters. These payments are common in biotech partnering and help reduce dependence on product launch timing.
Partnered development fees
Partnered development fees can give Trevi Therapeutics, Inc. non-dilutive R&D income from strategic partners or co-development deals, which helps fund work before launch. As Trevi Therapeutics, Inc. remains pre-commercial, this stream matters most when cash from external programs offsets high clinical-stage spend.
- Non-dilutive R&D funding
- From partners or co-development
- Helps before product launch
No marketed product revenue yet
Trevi Therapeutics, Inc. is still a clinical-stage Company, so it has no approved commercial product and no marketed product revenue. In its latest annual filings, revenue remained $0, so the business model depends on future FDA approval, launch, and then sales from any approved therapy.
- No product sales today
- Revenue starts only after approval
- Cash burn depends on R&D funding
Trevi's Revenue Still Hinges on Future Haduvio Sales
Trevi Therapeutics, Inc. had $0 revenue in fiscal 2025, so revenue streams still depend on future Haduvio sales after approval. The near-term cash mix is non-dilutive: Endo royalties, upfront and milestone fees, and partner R&D funding.
| Stream | FY2025 status |
|---|---|
| Product sales | $0 |
| Endo royalties | Contingent |
| Milestones / partner fees | Pre-launch |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.